Last reviewed · How we verify
Hydrochloride Carliprazine capsules
Carliprazine is an atypical antipsychotic that acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist.
Carliprazine is an atypical antipsychotic that acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist. Used for Schizophrenia, Bipolar disorder (acute mania/mixed episodes), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Hydrochloride Carliprazine capsules |
|---|---|
| Sponsor | Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2/D3 receptor partial agonist; Serotonin 5-HT1A receptor partial agonist |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Carliprazine modulates dopaminergic and serotonergic neurotransmission by binding to dopamine D2 and D3 receptors as a partial agonist, which helps normalize dopamine signaling in psychotic and mood disorders. It also acts as a partial agonist at serotonin 5-HT1A receptors, contributing to its anxiolytic and mood-stabilizing properties. This multi-target mechanism distinguishes it from first-generation antipsychotics and some other atypical agents.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania/mixed episodes)
- Major depressive disorder (adjunctive treatment)
Common side effects
- Akathisia
- Extrapyramidal symptoms
- Weight gain
- Sedation
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: